This result signifies that the patient has inherited one increased function allele and one decreased function allele. Based on the genotype result this patient is predicted to be an intermediate metabolizer of NAT2 substrates. This patient may be at risk for an adverse or poor response to medications that are metabolized by NAT2. To avoid an untoward drug response, dose adjustments or alternative therapeutic agents may be necessary for medications metabolized by NAT2. Please consult a clinical pharmacist for more information about how NAT2 metabolic status influences drug selection and dosing.